Latest Healthcare News

EVE Health Group has completed its acquisition of Nextract, raised $1 million to fund manufacturing, and achieved key regulatory and commercial milestones for its pharmaceutical products targeting erectile dysfunction and dysmenorrhea.

Doctor Care Anywhere has reported a landmark positive operating and investing cash inflow in Q2 2025, alongside modest consultation growth and strategic service expansion. The company reiterates its ambitious revenue and profitability targets amid ongoing cost transformation.

Osteopore Limited has posted a record AUD 835K revenue in Q2 CY25, driven by strong APAC sales and new European market access following EU MDR clearance. The company also advances clinical trials and refreshes key distribution channels.

TrivarX has secured key approvals and begun recruiting for its innovative mental health screening trial in US veterans, while also launching a wearable tech pilot with a Major League Baseball academy in the Dominican Republic.

Rhythm Biosciences has successfully validated its ColoSTAT® colorectal cancer test, secured its first strategic partnership for Genetype, and secured $1 million in non-dilutive funding, setting the stage for a transformative FY26.

Neurotech International reports encouraging Phase I human pharmacokinetic results for its pediatric cannabinoid drug NTI164, alongside published clinical trial data in Rett Syndrome and key regulatory progress in the US and Australia.

Amplia Therapeutics reports encouraging ACCENT trial results for its FAK inhibitor narmafotinib, including rare complete responses in pancreatic cancer, alongside a $27.5 million capital raise to fund ongoing clinical development.

INOVIQ Limited reports breakthrough results for its ovarian cancer screening test achieving perfect early-stage detection, alongside promising advances in its CAR-exosome cancer therapy program.

Next Science reports a 10% decline in quarterly product sales but advances a $50 million asset sale to Demetra Holdings, signaling a pivotal shift in its business strategy.

Enlitic, Inc. has confirmed its commitment to achieving operational cashflow break-even by the end of 2025, alongside maintaining its revenue guidance of US$9-11 million for the calendar year.

ImpediMed Limited reported a record quarter for its SOZO device sales with $6.3 million in contracts, supported by expanded US reimbursement coverage and new funding. Despite stable revenue, the company’s cost-cutting and strategic moves position it well for growth in FY26.

Island Pharmaceuticals has completed its acquisition of the broad-spectrum antiviral Galidesivir ahead of schedule, setting sights on expedited FDA approval leveraging the Animal Rule.